<DOC>
	<DOCNO>NCT01140867</DOCNO>
	<brief_summary>The object study ass efficacy safety zonisamide adjunctive therapy patient uncontrolled partial epilepsy .</brief_summary>
	<brief_title>Open-label , Multi-center Trial Zonisamide Adjunctive Therapy Patients With Uncontrolled Partial Epilepsy</brief_title>
	<detailed_description>The object study ass efficacy safety zonisamide adjunctive therapy patient uncontrolled partial epilepsy . Subject take zonisamide 16 week ( 4 weeks-titration period , 8 week maintenance period ) . Dose range zonisamide 100 ~ 400 mg/day target dose 300 mg/day . After 16 week , zonisamide efficacy measured seizure reduction rate ( Each type seizure : simple partial seizure [ SPS ] , complex partial seizure [ CPS ] , simple partial seizure evolve generalized tonic-clonic convulsion [ SGTC ] total seizure frequency ) , seizure free rate , responder rate , quality life epilepsy ( QOLIE-31 ) investigator 's global evaluation scale . Safety zonisamide study estimate adverse event profile , retention rate dose exposure . The duration clinical study 2 year include period subject enrollment .</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies , Partial</mesh_term>
	<mesh_term>Zonisamide</mesh_term>
	<criteria>Inclusion criterion : 1 . Epilepsy patient 15 year old agree Informed Consent Form 2 . Patient classifiable uncontrolled partial epilepsy accord International Classification Epileptic Seizures . 3 . Patient 3 ~ dozen partial seizure ( average seizure per 4 week ) last 12 week despite take 1 ~ 3 antiepileptic drug ( ) . 4 . Patient take 1 ~ 3 market antiepileptic drug ( ) exclude zonisamide point enrollment time . 5 . Before study visit , patient take stable dose antiepileptic drug 4 week . Exclusion criterion : 1 . Patient progressive central nervous system ( CNS ) disorder and/or degenerative disease brain . 2 . Patient experience pseudoseizures and/or uncountable cluster . 3 . Patient serious systemic drug metabolism affect disorder . 4 . Upward double normal glutamic oxaloacetic transaminase ( GOT ) , glutamic pyruvic transaminase ( GPT ) , bilirubin , blood urea nitrogen ( BUN ) , creatinine level . 5 . Patient absolute neutrophil count &lt; 1800/mm3 platelet &lt; 100,000/mm3 . 6 . Patient medical history renal stone . 7 . Patient allergic sulfonamide . 8 . Medical history medicinal poisoning and/or alcoholism and/or serious psychological disorder . 9 . Pregnant woman , lactate woman , woman childbearing age use preventive method conception . 10 . A terminal patient and/or schedule surgical patient . 11 . Patient medication history zonisamide . 12 . Patient participate clinical trial within last 12 week point enrollment time study .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>